ClinicalTrials.gg
RecruitingNCT06255535Updated Feb 21, 2025

pBFS Guided rTMS Over Cognitive Control Network for ASD

An interventional study of active iTBS treatment and sham iTBS treatment in Autism Spectrum Disorder, sponsored by Changping Laboratory. Recruiting at 6 sites in China. Open to participants aged 6 Years to 30 Years. Per ClinicalTrials.gov, last updated 2025-02-21.

Sponsored by Changping Laboratory · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
215
Allocation
Randomized
Ages
6 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies in Autism Spectrum Disorder with a site in China — 37 open to participants now, 38 under way, none of them phase 3. Autism Spectrum Disorder · China.

Planned enrollment
7th of 63
215 · median 96
Started
2024
with 13 others
No phase
50 of 86
21 open now
Primary completion
2026-04
later than 11 of 37 live
Registered
38th of 86
by date
Lead sponsor
4 of 86
Changping Laboratory

Among the 86 studies in Autism Spectrum Disorder with a site in China, this one is the 7th largest by planned enrollment of the 63 interventional ones that give a count, is one of 14 that started in 2024, is one of 50 with no phase, reaches primary completion later than 11 of the 37 other live ones, and was the 38th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

37 of the 86 studies in Autism Spectrum Disorder with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 6 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Autism Spectrum Disorder with a site in China, or all of them as a file.
02

Study summary

The aim of this trial is to assess the efficacy and safety of precision neuromodulation for alleviating core symptoms in patients with autism spectrum disorder (ASD) who also have intellectual or developmental delay. The neuromodulation will be administered using intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC), guided by personalized Brain Functional Sector (pBFS) technology.

Read the detailed description

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by impaired social communication and repetitive behaviors. Unfortunately, evidence-based treatments have not proven effective for older individuals with low-functioning ASD, despite their significant need for intensive support. However, emerging evidence suggests that Transcranial Magnetic Stimulation (TMS) has been successful in treating various psychiatric and neurological disorders.

Given the broad cognitive control dysfunction observed in ASD, targeting cognitive control function may offer a promising treatment approach. Leveraging the personalized Brain Functional Sector (pBFS) technique and task-free functional MRI scans, we can precisely locate the cognitive control function region within the left DLPFC, and follow-up at 24-week after initiation of treatment.

In this study, participants who meet the inclusion and exclusion criteria will be randomly assigned to either active or sham iTBS (intermittent theta burst stimulation) groups at a ratio of 2:1. The treatment protocol consists of a 12-week duration, with sessions conducted 5 days per week and 3 sessions iTBS over DLPFC per day. The inter-session interval is set at 30 minutes. Clinical evaluations focusing on ASD core symptoms and related behavioral profiles will be conducted at baseline and after the 12-week treatment period.

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • intellectual or development delay
  • personalized
  • TMS
  • functional MRI
04

Who can participate

Ages eligible
6 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 6-30 years old
  • Have the diagnosis of autism spectrum disorder
  • ADOS-2 score is higher than the ASD cut-offs
  • Comorbid with intelligent disorder, IQ/DQ \< 70
  • Primary environmental language is Chinese
  • Participant's parents or other legal guardians give

Exclusion criteria

Exclusion Criteria:

  • Genetic Disorders, such as (e.g., Down syndrome, Fragile X syndrome, Rett syndorme), Current or history of severe ADHD, tourette syndrome, psychotic disorders (e.g., schizophrenia, schizoaffective disorder, bipolar disorder)
  • Severe self-injury or suicidal behavior exhibited within the past year
  • Significant visual, auditory, deafness or motor disability that prevent them from following study procedures
  • Current or history diagnosis of epilepsy
  • Known severe physical diseases, particularly those affecting the brain
  • Metal implantation contradicted by MRI or TMS, such as artificial cardiac pacemakers, stents, cochlear implants
  • Respiratory or circulatory conditions increasing sedation risk, such as Apnea syndrome, severe snoring, or other relevant diseases
  • All legal guardians are illiterate, unable to read informed documents or complete questionnaires independently
  • Received transcranial magnetic stimulation (TMS), transcranial current stimulation (tCS), focused ultrasound (FUS), or other neuromodulation treatment in the last 3 months
  • Current participation in other clinical trials
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
215 participants (estimated)

Study arms

  • Experimental
    active iTBS group

    active iTBS over DLPFC

    Device: active iTBS treatment

  • Sham comparator
    Sham group

    sham iTBS over DLPFC

    Device: sham iTBS treatment

Interventions

  • Deviceactive iTBS treatment

    Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Individualized targets will be generated using the pBFS technique.

  • Devicesham iTBS treatment

    Participants will undergo three iTBS sessions per day, with 1800 pulses per session, over a 12-week period. Sham stimulation will be delivered through a sham coil with the identical appearance as real coil. Individualized targets will be generated using the pBFS technique.

06

What researchers measure

Primary outcomes

  1. ADOS-2 SA CSS score change after treatment

    The score changes of ADOS-2 SA CSS (Autism Diagnostic Observation Scale, 2nd edition, social affect domain, calibrated severity score) at 12-week from baseline. Higher scores mean a worse outcome.

    Time frame: Pre-treatment (baseline), post-treatment (12-week)

Secondary outcomes

  1. ADOS-2 SA CSS score change from baseline to follow-up

    The score changes of ADOS-2 SA CSS from baseline, to 12-week posttreatment and, to 24-week follow-up. Higher scores mean a worse outcome.

    Time frame: Pre-treatment (baseline), post-treatment (12-week), follow-up (24-week)

  2. Response rate in social ability after 12-week iTBS treatment

    Treatment response is defined as improvement, i.e., at least 1-point decreased, in the ADOS-2 SA For ADOS-2 SA, higher scores means more severe symptom.

    Time frame: Pre-treatment (baseline), post-treatment (12-week)

  3. Response rate in social ability at 24-week follow-up

    Treatment response is defined as improvement, i.e., at least 1-point decreased, in the ADOS-2 SA For ADOS-2 SA, higher scores means more severe symptom.

    Time frame: Pre-treatment (baseline), follow-up (24-week)

  4. ADOS-2 total CSS change with treatment

    The ADOS-2 total CSS score change from baseline. Higher scores mean a worse outcome.

    Time frame: Pre-treatment (baseline), post-treatment (12-week), follow-up (24-week)

  5. SCQ score change with treatment

    The SCQ (Social Communication Questionnaire) score change from baseline. Higher scores mean a worse outcome.

    Time frame: Pre-treatment (baseline), post-treatment (12-week), follow-up (24-week)

  6. CBCL score change with treatment

    The CBCL (Child Behavior Checklist) score change from baseline. Higher scores mean a worse outcome.

    Time frame: Pre-treatment (baseline), post-treatment (12-week), follow-up (24-week)

  7. QoL score change with treatment

    The QoL (quality of life) score change from baseline. Higher scores mean a worse outcome.

    Time frame: Pre-treatment (baseline), post-treatment (12-week), follow-up (24-week)

  8. AIM score change with treatment

    The AIM (Autism Impact Measure) score change from baseline. Higher scores mean a worse outcome.

    Time frame: Pre-treatment (baseline), post-treatment (12-week), follow-up (24-week)

07

Study locations

6 of 6 sites recruiting
  • Fujian Children's Hospital
    Fuzhou, Fujian, China
    Recruiting
  • Fujian Maternity and Child Health Hospital
    Fuzhou, Fujian, China
    Recruiting
  • Hebei Provincial Mental Health Center
    Baoding, Hebei, China
    Recruiting
  • Xi'an TCM Hospital of Encephalopathy
    Xi'an, Shaanxi, China
    Recruiting
    • Feng Gao · Contact
  • Jining Medical University
    Jining, Shandong, China
    Recruiting
  • Linyi Hedong Rehabilitation Hospital
    Linyi, Shandong, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2026, 24 months after the start.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 24 months is close to that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2024
First posted
Feb 13, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Apr 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Feb 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06255535
Lead sponsor
Changping Laboratory
Collaborators
Xi'an TCM Hospital of Encephalopathy, Linyi Hedong Rehabilitation Hospital, Jining Medical University, Fujian Maternity and Child Health Hospital, Fujian Children's Hospital, Hebei Provincial Mental Health Center
Responsible party
Sponsor
First posted
Feb 13, 2024
Start date
Apr 1, 2024
Primary completion
Apr 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Feb 21, 2025

Study contacts

Qi Liu, Ph.D.
Contact
liuqi@cpl.ac.cn
010-80726688
Hesheng Liu, Ph.D.
study chair · Changping Laboratory

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion